Search | Clinical Trials Finder

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: acute resistance exercise with oral nutrition supplementation, stable tracer infusion; Other
Lead sponsor: Texas A&M University; Other
Eligibility: 45 Years to 100 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: College Station, Texas

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: placebo to tiotropium + olodaterol, tiotropium +olodaterol, tiotropium; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 3
States / cities: San Diego, California • Torrance, California • Hartford, Connecticut

Conditions: Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions: beclomethasone dipropionate; Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 5 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Chronic Primary Insomnia
Interventions: ACT-078573 oral capsules at 25 and 100 mg and matching placebo, ACT-078573 and matching placebo; Drug
Lead sponsor: Midnight Pharma, LLC; Industry
Eligibility: 65 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 21
States / cities: Hot Springs, Arkansas • Los Angeles, California • San Diego, California + 16 more

Conditions: Purpura, Thrombocytopaenic, Idiopathic
Interventions: eltrombopag; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 2
States / cities: Gainesville, Florida • Saint Paul, Minnesota

Conditions: Chronic Hepatitis b
Interventions: ATI-2173 50 mg; Drug
Lead sponsor: Antios Therapeutics, Inc; Industry
Eligibility: 18 Years to 59 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Cypress, California

Conditions: Lymphoma
Interventions: rituximab, clofarabine, DNA methylation analysis, gene expression analysis, microarray analysis, polymerase chain reaction, high performance liquid chromatography, laboratory biomarker analysis; Biological · Drug · Genetic + 1 more
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years to 89 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: QBW251, Placebo, COPD maintenance background therapy; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 974 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 25
States / cities: Andalusia, Alabama • Los Angeles, California • Westminster, California + 22 more

Conditions: Hypoalbuminemia, Protein-energy Malnutrition, Inflammation, Oxidative Stress, Chronic Kidney Disease (CKD) Hemodialysis
Interventions: pentoxiphylline, Nepro, anti-inflammatory module (similar to Oxepa), Placebo pill imitating pentoxiphylline, Placebo to imitate Nepro, Placebo to imitate anti-inflammatory module (similar to Oxepa); Drug · Dietary Supplement
Lead sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center; Other
Eligibility: 18 Years to 85 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Irvine, California • Torrance, California

Conditions: Chronic Pain, Nociceptive Pain
Interventions: CNTX-6970, Placebo; Drug · Other
Lead sponsor: Centrexion Therapeutics; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Hepatitis C, Chronic Pain
Interventions: Alisporivir, Peginterferon alfa-2a, Ribavirin; Drug
Lead sponsor: Debiopharm International SA; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 16
States / cities: La Jolla, California • San Diego, California • Ventura, California + 9 more

Conditions: Chronic Graft Versus Host Disease Oral
Interventions: Tacrolimus; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 1 Year to 40 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelomonocytic Leukemia
Interventions: Clofarabine; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Candidiasis, Oral, HIV Infections
Interventions: Fluconazole; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 948 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2002
U.S. locations: 53
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 28 more

Conditions: Dialysis, Anemia
Interventions: Roxadustat, Oral Iron, IV Iron; Drug
Lead sponsor: Kyntra Bio; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 3
States / cities: Northridge, California • Yuba City, California • Detroit, Michigan

Conditions: Gulf War Illness, Chronic Fatigue, Neurocognitive Dysfunction
Interventions: Cal-Mag Butyrate, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 40 Years to 70 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Long Beach, California • Miami, Florida • Salt Lake City, Utah

Conditions: Heart Transplant
Interventions: L-arginine; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 8 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Head and Neck Cancer, Radiation Toxicity, Xerostomia
Interventions: questionnaire administration, electroacupuncture therapy, management of therapy complications, quality-of-life assessment; Other · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 21 Years to 89 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Autoimmune Diseases, Lupus Erythematosus, Systemic, Communicable Diseases
Interventions: Not listed
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 2,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2028
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: XL844; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 3
States / cities: Duarte, California • San Diego, California • Houston, Texas

Conditions: Primary Progressive Multiple Sclerosis
Interventions: FTY720, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 970 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 33
States / cities: Newport Beach, California • Sacramento, California • Aurora, Colorado + 29 more

Conditions: Fibromyalgia, Multiple Sclerosis, Osteoarthritis, Sjögren's Syndrome, Parkinson's Disease
Interventions: Computer Tablet Group, Paper and Pencil Group, Contact Control Group; Behavioral
Lead sponsor: Case Western Reserve University; Other
Eligibility: 18 Years to 76 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Oral Complications, Radiation Toxicity
Interventions: filgrastim, palifermin, cyclophosphamide, etoposide, ifosfamide, quality-of-life assessment, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 12 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Myelofibrosis, MPN - Accelerated or Blast Phase, Chric Phase MPN
Interventions: Oral THU-decitabine; Drug
Lead sponsor: John Mascarenhas; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2033
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Oral Supplement and Acute Resistance Exercise

To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of Airways

Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon

Almorexant (ACT-078573) in Elderly Subjects With Chronic Primary Insomnia

Study Of SB-497115 in Healthy Subjects and Subjects With Mild, Moderate or Severe Renal Impairment

Ethnobridging Study in Healthy Volunteers, Chinese and Japanese Subjects

Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma

Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients

Anit-Inflammatory and Anti-Oxidative Nutrition in Dialysis Patients

A Placebo-Controlled, Two-Part Study, Oral Dose to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of CNTX-6970 in Healthy Subjects

Efficacy and Safety of Alisporivir Alone or Combined With RBV or PEG in Chronic Hepatitis C Genotype 2 and 3 Treatment-naïve Participants

Tacrolimus Toothpaste for Management of Oral Chronic Graft vs. Host Disease (cGVHD)

PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias

A Study to Compare the Use of Fluconazole as Continuous Therapy Versus Periodic Therapy in HIV-Positive Patients With Recurrent Thrush

Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Erythropoiesis-Stimulating Agent Treatment

Ca-Mg Butyrate in GWI

Prospective L-arginine Study

Electroacupuncture in Treating Chronic Dry Mouth Caused By Radiation Therapy in Patients With Head and Neck Cancer

Comparative Autoantibody and Immunologic Cell Marker Study

Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemia

This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.

e-Mobile Tablet for People With Chronic Conditions

Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer

Oral Tetrahydrouridine-Decitabine in Patients With Advanced Myeloproliferative Neoplasms